Description
Semax Capsules | ACTH-Derived Nootropic Neuropeptide — Research Grade
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide derived from the ACTH(4-7) core sequence, registered as a drug in Russia for stroke and cognitive impairment treatment. This oral capsule format (10mg per capsule, 60 capsules) provides a stable delivery method for research examining BDNF regulation, neuroprotection, and cognitive biology.
Mechanism of Action
- BDNF and NGF upregulation — significantly increases brain-derived and nerve growth factor expression in hippocampus and cortex
- Dopaminergic modulation — enhances dopamine turnover in prefrontal cortex, relevant to working memory and attention models
- Neuroprotection — reduces ischaemia-induced neuronal death and inflammatory cytokine release in stroke models
- HIF-1α pathway — modulates hypoxia-inducible factor signaling under oxygen-glucose deprivation conditions
Research Areas
Semax is studied in stroke recovery, cognitive impairment, ADHD models, anxiety, and neuroprotection research. Frequently paired with Selank as a complementary neuropeptide pair and with Dihexa for synaptogenesis research.
For Research Use Only. Rainbow Peptide supplies this compound exclusively for in vitro and laboratory research purposes. Not for human or veterinary use.
Dr. I. Volkov –
Semax capsules for oral BDNF and cognitive research. Content confirmed >99% pure. Capsule weight uniformity ±2% of label. COA detailed. Our oral bioavailability model showed measurable neuroprotective activity.
M. Bjornsen –
10mg Semax capsules — excellent format for our oral nootropic research. Content purity confirmed. COA thorough. Capsule dissolution in our model was consistent and reproducible. Fast delivery.
A. Kamau –
Good Semax capsules. Content >98.5% purity verified. Capsule uniformity acceptable. COA comprehensive. Practical format for oral route peptide research.